Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Karyopharm Therapeutics (KPTI) Other Gross PP&E Adjustments (2016 - 2025)

Karyopharm Therapeutics' Other Gross PP&E Adjustments history spans 14 years, with the latest figure at -$1.8 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments rose 57.55% year-over-year to -$1.8 million; the TTM value through Dec 2025 reached -$1.8 million, up 57.55%, while the annual FY2025 figure was -$1.8 million, 57.55% up from the prior year.
  • Other Gross PP&E Adjustments reached -$1.8 million in Q4 2025 per KPTI's latest filing, up from -$4.7 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of -$1.8 million in Q4 2025 to a low of -$12.8 million in Q4 2021.
  • Average Other Gross PP&E Adjustments over 5 years is -$6.2 million, with a median of -$5.5 million recorded in 2023.
  • The largest YoY upside for Other Gross PP&E Adjustments was 57.55% in 2025 against a maximum downside of 80.97% in 2025.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at -$12.8 million in 2021, then increased by 3.91% to -$12.3 million in 2022, then skyrocketed by 54.33% to -$5.6 million in 2023, then rose by 25.82% to -$4.2 million in 2024, then soared by 57.55% to -$1.8 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Other Gross PP&E Adjustments are -$1.8 million (Q4 2025), -$4.7 million (Q3 2025), and -$5.1 million (Q2 2025).